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Autophagy is an evolutionary conserved physiological process with a fundamental role
during development, differentiation, and survival of eukaryotic cells. On the other hand,
autophagy dysregulation is observed in many pathological conditions, including cancer. In
particular, tumor growth and progression are accompanied and promoted by increased
autophagy that allows cancer cells to escape apoptosis and to proliferate also in harsh
microenvironments. It is, therefore, clear that the impairment of the autophagic process
may represent a valid strategy to inhibit or reduce cancer growth and progression. Among
the plethora of molecular players controlling cancer growth, a group of small endogenous
noncoding RNAs called microRNAs (miRNAs) has recently emerged. In fact, miRNAs can
act as either oncogenes or oncosuppressors depending on their target genes. Moreover,
among miRNAs, miRNA-34a has been connected with both tumor repression and
autophagy regulation, and its expression is frequently lost in many cancers. Therefore,
enforced expression of miRNA-34a in cancer cells may represent a valid strategy to
reduce cancer growth. However, such strategy is limited by the fast biodegradation and
short half-life of miRNA-34a and by the lack of an efficient intracellular delivery system. The
following review describes the autophagic process and its role in cancer as well as the role
of miRNAs in general and miRNA-34a in particular in regulating tumor growth by
modulating autophagy. Finally, we describe the use of nanoparticles as a promising
strategy to selectively deliver miRNA-34a to tumor cells for therapeutic and
diagnostic purposes.
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Autophagy is an intracellular process with a role in several
pathological conditions including cancer, neurodegenerative
disorders, and infectious diseases (Mizushima et al., 2011;
Deretic et al., 2013; Dikic and Elazar, 2018), all processes in
which cytosolic wastes are delivered to the lysosomes for
degradation and recycling (Mizushima et al., 2011). Recently,
Yoshinori Ohsumi was awarded the Nobel prize for his studies
on the basic mechanisms of autophagy in yeast (Tooze and Dikic,
2016). However, the understanding of the molecular
mechanisms controlling autophagy induction and modulation
in the physiopathology of mammalian cells is still far from
being elucidated.
MiRNAs are endogenous small noncoding RNAs that
participate in the regulation of gene expression, whose
dysregulation is mechanistically implicated in many
pathological processes, including autophagy and tumorigenesis
(Wang et al., 2013; Peng and Croce, 2016). Among the plethora
of miRNAs analyzed, miRNA-34a expression is abnormally
regulated in many cellular processes, including cell division,
senescence, apoptosis, autophagy, and tumorigenesis (Huang
et al., 2014). Hence, since the two latter processes are tightly
connected, the re-establishment of endogenous intracellular
levels of miRNAs and, especially, of miRNA-34a may block
pathologic autophagy and counteract cancer progression.
However, the low stability of miRNAs and their difficult
delivery into cells restrict their application in clinical practice
(Chen et al., 2015).
In this sense, advances in nanotechnology have led to the
development of many different nanostructures, which can be
employed as drug delivery systems to improve the properties of a
variety of bioactive compounds, including nucleic acids (Mei
et al., 2019). For these reasons, nanocarriers are being explored to
convey therapeutic miRNAs in order to interfere with
key biological processes involved in tumor progression,
including autophagy.
In this review, we summarize recent studies describing the use
of nanoparticles for the delivery of miRNA-34a in cancer cells,
alone or in combination with traditional chemotherapy drugs for
the inhibition of different oncogenic pathways, with emphasis on
autophagy regulation. Hence, the delivery of miRNA-34a
combined to nanostructures may improve its biodistribution
and accumulation at the target site, with some papers showing
encouraging results, both in in vitro and in vivo studies.AUTOPHAGY: WHEN THE CELLS EAT
THEMSELVES
Autophagy is an evolutionarily conserved cellular homeostatic
process that consists in the formation of double-membrane
structures that engulf cytosolic wastes, including damaged
organelles, protein aggregates, or invading pathogens, and fuse
with lysosomes to degrade their content (Mizushima et al., 2011).
Autophagy is further subdivided into several categoriesFrontiers in Pharmacology | www.frontiersin.org 2depending on its site of action, for instance, when it takes
place in pathogens is called xenophagy (Levine, 2005),
mitophagy in the mitochondria (Narendra et al., 2008),
pexophagy in the peroxisomes (Nazarko et al., 2007), ERphagy
in the endoplasmic reticulum (Chino et al., 2019. Khaminets
et al., 2015), or lysophagy in the lysosomes (Maejima et al., 2013).
Other relatively less studied forms of autophagy, called chaperon
mediated autophagy involve molecular chaperones, such as
HSP70 (Kaushik et al., 2006). Chaperone mediated autophagy
does not require the whole autophagy machinery but involves the
recruitment of the lysosomal membrane protein LAMP2 to
substrate such as protein aggregates, damaged organelles and
invading pathogens through chaperons and ultimately the
degradation of the cargo (Kaushik et al., 2006). Chaperon
mediated autophagy has several medical implications, including
a role in cancer (Kaushik et al., 2011). Microautophagy is another
form of autophagy that is mediated by the direct engulfment of
cytoplasm and its components by membrane invaginations into
lysosomes. A role of microautophagy has been demonstrated in
various pathologies (Li et al., 2012). Another form of autophagy
called LC3 dependent phagocytosis (LAP) has also been reported
(Sanjuan et al., 2007). Unlike conventional autophagy, LAP
involves the formation of a single membrane structure positive
for autophagy marker LC3 around the phagocytic substrate and
ultimately its fusion with the lysosome. Like conventional
autophagy, LAP requires autophagy conjugation machinery
(discussed in the next section) but does not require
components of autophagy initiation machinery (Martinez
et al., 2015). Another major difference between LAP and
conventional autophagy is that LAP requires RUBICON (Run
domain Beclin-1 interacting and cysteine-rich containing
protein), which is an inhibitor of the conventional autophagy
(Martinez et al., 2015). Like all other forms of autophagy, the role
of LAP has been studied in various pathologies, such as
inflammation related disorders (Martinez et al., 2016),
neurodegeneration (Heckmann et al., 2019), and cancer
(Cunha et al., 2018).
Role of Autophagy in Cancer
The role of autophagy in cancer is somewhat controversial.
Earliest reports suggested a role of autophagy against
tumorigenesis (Liang et al., 1999) and afterwards, several
reports found a role of autophagy favoring cell death of tumor
cells in an apoptotic-dependent or independent way (Levine and
Yuan, 2005; Pattingre et al., 2005; Kumar et al., 2013; Sierra et al.,
2015). On the other hand, it was demonstrated that inhibition of
autophagy could also hamper the antitumor T cell response,
which is required for immunogenic cell death (Townsend et al.,
2012; Ma et al., 2013). However, the observation that in a
different setting the inhibition of autophagy does not suppress
the immune response suggests the existence of autophagy-
independent mechanisms of the immune response (Starobinets
et al., 2016). Therefore, the role of autophagy in immunogenic
cell death in cancer may vary from one condition to other, and
no conclusion can be drawn based on the present literature. All
these studies suggest that autophagy plays a dual role in cancer:July 2020 | Volume 11 | Article 1141
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tumorigenesis, whereas at later stages cancer cells may utilize
this process to escape from apoptosis and to promote
uncontrolled growth, as well as resistance to stress”. However,
to better clarify the proproliferative role of autophagy in cancer,
many efforts have been made by using pharmacological
modulators for cancer therapy (Amaravadi et al., 2007; Levy
et al., 2017; Amaravadi et al., 2019). For instance, autophagy
inhibitors chloroquine (CHQ) and hydroxychloroquine (HCQ)
are being tested against different types of cancer (Levy et al.,
2017; Amaravadi et al., 2019). Both CHQ and HCQ inhibit the
fusion between autophagosomes and lysosomes occurring at the
final stage of the autophagic process (Klionsky et al., 2016).
Moreover, proteins active in different stages of autophagy are
being analyzed as potential therapeutic targets in cancer.
Autophagy is initiated by the ULK1 complex, and inhibition of
ULK1 has shown encouraging results in cancer therapy (Egan
et al., 2015; Martin et al., 2018). Likewise, suppression of FIP200,
another component of autophagy initiation complex, also
induces apoptosis, and inhibition of FIP200 limits early
tumorigenesis and also the progression of breast cancer in a
mouse model (Wei et al., 2011; Xia et al., 2017). Inhibition of
VPS34 has also shown promising results (Dowdle et al., 2014;
Ronan et al., 2014). ATG4B, which is required for the processing
of mAtg8s and consequently, for the progression of autophagy, is
also being targeted to inhibit cancer progression (Levy et al.,
2017). Metabolism is one of the targets in cancer therapy.
Autophagy also plays an important role in maintaining cancer
cell metabolism (Rabinowitz and White, 2010; Guo et al., 2011).
More recently, it was shown that autophagy is required for
maintaining high circulating arginine levels necessary to
promote cancer progression (Poillet-Perez et al., 2018). Also,
proteins with multiple roles in autophagy could be targeted. An
example is Stx17, which acts in different steps of autophagy: it
regulates the formation of earliest autophagosomal structures
(Kumar et al., 2019) and consequently the initiation of
autophagy (Hamasaki et al., 2013; Sugo et al., 2018; Kumar
et al., 2019). Moreover, Stx17 is a key regulator of fusion between
autophagosomes and lysosomes (Diao et al., 2015), and this step
is being targeted in various cancer using chloroquine and
hydroxychloroquine (Levy et al., 2017). All these reports put
forward the role of autophagy regulators like Stx17 as a potential
new target in cancer therapy. Figure 1.MIRNAS IN CANCER
MicroRNAs (miRNAs) are a class of small endogenous noncoding
RNAs of about 21–25 nucleotides that modulate gene expression by
binding to the 3′-UTR region of a specific mRNA target. The main
effect of the miRNA binding is the decreased expression of specific
RNA sequences with consequences on several biological processes,
including cell proliferation, differentiation, apoptosis, development,
and tumorigenesis (Esquela-Kerscher and Slack, 2006). Indeed, the
alteration of miRNA expression pattern has been shown to support
cancer initiation, progression and dissemination (Berindan-NeagoeFrontiers in Pharmacology | www.frontiersin.org 3and Calin, 2014). Increasing evidences have shown that, depending
on their target genes, miRNAs can sustain tumor, by acting as either
oncogene or tumor suppressor, thus favoring evasion from growth
suppressors, support of proliferation, resistance to cell death,
angiogenesis, and activation of invasion and metastasis (Peng and
Croce, 2016). In many cancer types, miRNA profile is abnormal due
to gene amplifications or deletions, alteration of their transcriptional
control, epigenetic dysregulations and defects in the miRNA
biogenesis machinery. In particular, miRNA-34a, a tumor-
suppressor miRNA that belongs to an evolutionarily conserved
family of miRNAs, is deregulated in many human tumor types,
including breast, lung, prostate cancer, cholangiocarcinoma, acute
myeloid leukemia (AML), and multiple myeloma (MM). MiRNA-
34a plays a key role in many cellular processes, including the
regulation of cell division, senescence, apoptosis, and proliferation
(Huang et al., 2014). Indeed, in prostate cancer, one of the most
frequently diagnosed tumors, it has been shown that, among the 50
altered miRNAs that act in carcinogenesis, miR-34a expression is
strongly downregulated (Liao et al., 2016). MiRNA-34a decreased
expression may lead to a reduction in cell cycle arrest and apoptosis
and to the enhancement of chemoresistance and autophagy. Also, in
cholangiocarcinoma miR-34a downregulation is implicated in drug
resistance and in the control of epithelial–mesenchymal transition
(EMT) through an effect on Smad4 (Sun et al., 2017). Interestingly,
the enforced expression of miR-34a inMMcells or its delivery in the
tumor xenografts by direct intratumor or intravenous injection
mimics the effect of other anticancer agents without producing
toxicity, thus representing a new therapeutic strategy (Di Martino
et al., 2014). Thus, all this evidence supports the analysis in tumors
of miRNAs, and in particular of miRNA-34a, as well as the artificial
restoration of their physiological levels for both diagnostic and
therapeutic purposes.
miRNA-34a in Autophagy Regulation
Many studies have investigated the multiple effects associated
with the decreased expression of miRNA-34a in support of
tumor growth, showing that this miRNA is also an important
regulator of autophagy (Figure 2). Indeed, Liao et al.
demonstrated that in prostate cancer, miRNA-34a expression
is decreased due to gene hypermethylation, correlating with
higher cell proliferation, apoptosis abrogation, enhanced
chemoresistance, and autophagy induction (Liao et al., 2016).
By overexpressing miR-34a, they showed that the autophagy-
related proteins, ATG4B, Beclin-1, and LC3B II/I, were
downregulated. This led to enhanced chemosensitivity to the
drugs doxorubicin and topotecan. Furthermore, they showed
that the downregulation of miRNA-34a expression parallels the
upregulation of ATG4B-induced autophagy through the AMPK/
mTOR pathway regulation (Liao et al., 2016). Another study on
colorectal cancer showed that the treatment with oxaliplatin
decreased the level of miRNA-34a, with the consequent increase
of drug resistance due to the activation of autophagy. This
activation has been shown to be mediated by the regulation of
the TGF-b/Smad4 pathway. Indeed, 34a in colorectal cancer
patients the expression of Smad4 and miRNA-34a show a
significant inverse correlation and the overexpression ofJuly 2020 | Volume 11 | Article 1141
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Smad4 through the TGF-b/Smad4 pathway (Sun et al., 2017).
The high mobility group box 1 (HMGB1) is an ubiquitous
nuclear protein that regulates several DNA-related activities such
as transcription, replication, recombination, and repair (Liu
et al., 2014). HMGB1 is overexpressed in different tumor types
and has been proposed as a target for cancer therapy (Lugrin
et al., 2014). Among its multiple functions supporting tumor
proliferation, HMGB1 improves chemotherapy resistance
through the induction of autophagy in human myeloid
leukemia cells (Liu et al., 2011). Interestingly, in acute myeloid
leukemia (Liu et al., 2017) and in retinoblastoma cells (Liu et al.,
2014), the induction of HMGB1 parallels a decreased expression
of miRNA-34a, which targets HMGB1 mRNA, leading to
reduced apoptosis and induction of autophagy.
As described previously, the ATG protein family is composed
of 35 autophagy-related (Atg) genes: Atg1-10, 12-14, 16-18, 29,
and 31 are essential for the formation of autophagosomes
(Mizushima et al., 2011). Among these, Atg9 has attracted
much attention because it is the only transmembrane proteinFrontiers in Pharmacology | www.frontiersin.org 4among the core Atg proteins required for autophagosome
formation. Fan et al. have shown that the inhibition of miR-
34a restored the expression of Atg9a and significantly decreased
ethanol-induced inhibition of autophagy and neural
differentiation of neural crest cells (Fan et al., 2019). Huang
et al. showed that miR-34a also modulates the expression of
Atg9a during myocardial hypertrophy (Huang et al., 2014).
These studies offer the cue to further investigations directed to
the exploration of Atg9a mRNA regulation by miRNA-34a also
in cancer cells.DELIVERY OF AUTOPHAGY-RELATED
MIRNA-34A WITH NANOPARTICLES
As described before, the ability of miRNA-34a to target
autophagy-related genes, such as ATG4 (Wu et al., 2017),
ATG5 (Cheng et al., 2019), ATG9 (Yang et al., 2013), and
HMGB1 (Liu et al., 2014; Liu et al., 2017) has attracted
considerable interest as a novel tool for anticancer therapy.FIGURE 1 | Main machinery and steps involved in autophagy. Autophagy involves different steps; assembly of ULK1 complex, which is negatively regulated by
mTOR, which phosphorylates ULK1 and inhibits autophagy; AMPK phosphorylates ULK1 and activates autophagy initiation, AMPK might also affect this process by
inhibiting mTOR activity by phosphorylating RAPTOR and TSC2. Autophagy initiation and assembly of ULK1 complex are controlled by TBK1 and its substrate
Stx17. TBK1 and Stx17 also affect the formation of mPAS, which is then elongated to a cup-like phagophore by the action of WIPIs, ATG2, ATG9, and PI3K
complex which comprises of VPS34, ATG14, and Beclin1. ATG conjugation machinery also helps in elongation and lipidation of the membrane. Once
autophagosome is completed SNARE protein Stx17 gets recruited to autophagosomes and works together with SNAP29 and VAMP8 to regulate fusion between
autophagosomes and lysosomes. Additional factors like HOPS, PLEKHM1, EPG5, and ATG14 help Stx17 in this process. Abbreviations: ATG, Autophagy related;
AMPK, 5′ AMP-activated protein kinase; TBK1, TANK Binding Kinase 1; mTOR, mammalian Target of Rapamycin; SNARE, soluble NSF (N-ethylmaleimide-sensitive
factor) attachment protein receptors).July 2020 | Volume 11 | Article 1141
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is now a promising tool to counteract tumor progression
(Farooqi et al., 2017).
However, miRNAs share some properties, such as rapid
biodegradation and short half-life in systemic circulation, poor
biocompatibility, low membrane penetrability, and excessive off-
target accumulation, that have greatly limited their application in
in vivo systems so far (Chen et al., 2015). Thus, due to the
growing awareness regarding the potential role of miRNA-34a in
cancer therapy, many efforts have been addressed to optimize
strategies for the targeted delivery of this miRNA.
In this sense, nanomedicine has emerged as a promising
technology allowing the accumulation of systemically
administered chemotherapeutics in the tumor tissues via the
enhanced permeability and retention effect (EPR) due to leakyFrontiers in Pharmacology | www.frontiersin.org 5tumor vasculature and poor lymphatic drainage (Wilhelm et al.,
2016). Extensive research focusing on developing cancer
nanomedicine has generated nanostructures capable of
overcoming biological barriers and transport chemotherapeutic
drugs to the targeted sites while minimizing harmful effects on
healthy tissues (Jain and Stylianopoulos, 2010). Moreover, the
surface of nanoparticles (NPs) can be chemically modified by
conjugating functional moieties, such as nucleic acids and
targeting ligands, for increasing targeted delivery to the tumor
sites, maximizing chemotherapy efficacy (Jabir et al., 2012).
Thus, the delivery of miRNA-34a combined to nanostructures
may overcome the weakness described above and function as
antisense strategy to inhibit oncogenic mRNAs, involved in
autophagy induction, or to restore the physiological levels of
tumor suppressor miRNA-34a. Different examples regarding theFIGURE 2 | Effect of miRNA34a inhibition on autophagy. Schematic representation of promoter methylation, which represents the most common cause of
miRNA34a decreased expression in tumors and of the principal effects of miRNA34a low expression in the sustainment of cancer proliferation. Particularly, we
highlighted the main pathway involved in the regulation of autophagy by miRNA-34a.July 2020 | Volume 11 | Article 1141
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miRNA, alone or in combination with other anticancer drugs, are
commented below (Figure 3).PREPARATION TECHNIQUES TO LOAD
MIRNA IN NANOPARTICLES
Several techniques such as emulsion based techniques (Cohen-
Sela et al., 2009), nanoprecipitation (Alshamsan, 2014),
interfacial polymerization (Singha et al., 2011) are used for
preparation of NPs to load miRNAs. Some methods are more
efficient than others based on the surface characteristics.
Emulsion based nanoparticles are most commonly used
methods for delivery of NPs. Emulsion based delivery method
utilizes ultrasonication (Shi et al., 2014) and homogenization
followed by purification at high speed centrifugation (Cosco
et al., 2015). Single or double emulsion techniques are used for
delivery of NPs (Jenjob et al., 2019). Oil in water emulsion is an
example of single emulsion technique which can be used to
encapsulate hydrophobic and hydrophilic drugs in micro- orFrontiers in Pharmacology | www.frontiersin.org 6nanoscale form. In single emulsion technique Poly(lactic-co-
glycolic acid) (PLGA), one of the ideal reagent for nanoscale
delivery (McCall and Sirianni, 2013), is dissolved into an organic
phase (oil) that is emulsified with a surfactant or stabilizer
(water). Hydrophobic drugs are added directly to the oil phase,
whereas hydrophilic drugs (water) may be first emulsified with
the polymer solution prior to the formation of particles (McCall
and Sirianni, 2013; Jenjob et al., 2019). Double emulsion-solvent
evaporation method has potential for encapsulation of both
hydrophilic and hydrophobic payloads with high encapsulation
efficiency and utilizes two emulsification steps to obtain water-
in-oil-in-water (w/o/w) or oil-in water-in-oil (o/w/o) emulsions
(McCall and Sirianni, 2013; Jenjob et al., 2019).
Another technique used for delivery of NPs is nanoprecipitation.
It is a less complex and widely applicable method for
hydrophobic drug molecules (Salatin et al., 2017). It is a solid
displacement method which requires solvent (organic) and
nonsolvent (inorganic) phase separation followed by addition
of one phase to another (Salatin et al., 2017). Both the drug and
the polymer for the delivery must be dissolved in solvent; once
the solvent is mixed to a nonsolvent rapid desolvation andFIGURE 3 | Nanoparticles for delivery of miRNA-34a for autophagy inhibition. Schematic representation showing the effects of nanoparticles functionalized with anti-
autophagy miRNA-34a in cancer cells. Upon intracellular stimulus, NPs can release therapeutic miRNA-34a and restore its cellular physiological levels. miRNA-34a
can exert its tumor suppressor activity by downregulating autophagy-related genes and inhibiting protective autophagy. Blocking cancer autophagy leads to cancer
cell death either directly or by sensitizing them to chemotherapy treatment.July 2020 | Volume 11 | Article 1141
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et al., 1989; Martıńez Rivas et al., 2017). Solvents miscible with
water and nonhalogenated solvents are commonly used;
however, immiscible solvents such as dichloromethane can also
be used (Salatin et al., 2017). One example is mixing of
cucurbitacin I and PLGA in acetone. The organic phase is
added dropwise to deionized water containing 1% Pluronic F-
68 followed by acetone evaporation (Alshamsan, 2014). Another
example in which miRNA-loaded PLGA/chitosan (PLGA/CS)
NPs of 150–180 nm size are prepared via the nanoprecipitation
method is by dropwise addition of PLGA solution into a water
solution of CS and miR-34s in the presence of a Poloxamer
surfactant (Salatin et al., 2017).
Interfacial polymerization is another technique used to
deliver NPs. Using this approach hydrophilic substances such
as miRNAs are incorporated into biodegradable lignin
nanocontainers (Wurm and Weiss, 2014). This technique
involves copolymerization of hydrophobic and hydrophilic
monomers to constrain the polymerization at interfaces, but its
free-radical mechanism allows precise control of initiation,
which makes it possible to finely disperse the immiscible
phases prior to polymerization (Scott et al., 2005). The
interfacial polymerization falls into different types of interfaces:
liquid–solid interfaces, liquid–liquid interfaces, and liquid-in-
liquid emulsion interfaces (Song et al., 2017). There are also
other interface categories, rarely used, including liquid–gas,
solid–gas, and solid–solid (Salatin et al., 2017; Song et al., 2017).
Inorganic Nanoparticles
Recent advancement in nanotechnology has led to the
introduction of various inorganic nanomaterials, such as silica
dioxide nanoparticles (SiO2-NPs), calcium phosphate
nanoparticles (CaP-NPs), gold nanoparticles (AuNPs), gold
nanoshells (AuNShs), and magnetic nanoparticles (MNPs) that
have been exploited as excellent nanocarriers for the delivery of
nucleic acids both in vitro and in vivo models (Naz et al., 2019).
These nanomaterials share some properties such as high
bioactivity, biocompatibility, and chemical stability that make
them efficient delivery systems (Cheng and Kuhn, 2007; Ghosh
et al., 2008; Park et al., 2009; Tang et al., 2012; Xu et al., 2014;
Xiong et al., 2018). Recently, it has been reported that SiO2-NPs
can efficiently deliver active miR-34a into breast cancer cells
leading to the reduction in mammosphere formation
(Panebianco et al., 2019) and the downregulation of Notch-1, a
well-established miR-34a target with an important role in
regulating stem cell functions and autophagy process (Bouras
et al., 2008; Marcel and Sarin, 2016). Notably, in vivo miR-34a
delivery by SiO2-NPs was able to exert a tumor-suppressive
function leading to the reduction of breast cancer in engrafted
mice (Panebianco et al., 2019) (Table 1).
In a study performed byMok et al., a long chainmiRNA-34a (lc-
miRNA-34a) was prepared by chemical crosslinking in order to
improve encapsulation efficiency into linear polyethyleneimine
(LPEI)-coated CaP-NPs (LPEI-CaP) and intracellular delivery
(Jung et al., 2015). These nanoformulations were successfully
delivered into PC-3 cancer cells, where miRNA-34a was efficientlyFrontiers in Pharmacology | www.frontiersin.org 7released, suppressing cancer cell proliferation as well as cell
migration (Jung et al., 2015).
In another study by Milán-Rois et al., a therapeutic mixture
containing SN-38(7-ethyl-10-hidroxycamptothecin), a
topoisomerase inhibitor (Palakurthi, 2015), and miRNA-34a
has been delivered in uveal melanoma cells using AuNPs
(Milán Rois et al., 2018). The nanoformulations led a
synergistic cytotoxicity effect in cancer cells and were able to
reprogram their oncogenic phenotype by downregulating c-MET
tyrosine kinase, making Mel-202 cancer cells more susceptible to
SN-38 (Milán Rois et al., 2018).
Other inorganic nanostructures widely used in biomedical
applications are gold nanoshells (AuNShs), which are composed
of an inorganic core coated with a thin layer of gold (Bardhan
et al., 2011).
In a recent study, Goyal et al. reported that layer-by-layer
assembled gold nanoshells (LbL-AuNShs) were able to efficiently
deliver miRNA-34a to MDA-MB-231 breast cancer cells and
release it upon intracellular stimulus (Goyal et al., 2018).
Notably, the cancer cells treated with these inorganic
nanostructures downregulated the expression of the
autophagy-modulators SIRT1 and Bcl2, which are known
downstream targets of miRNA-34a (Li et al., 2013). Moreover,
treatment with LbL-AuNSsh affected the proliferation and
metabolic activity of triple-negative breast cancer cells without
negatively impacting noncancerous MCF10A breast epithelial
cells (Li et al., 2013).
MNPs are ideal candidates for surface modifications
generating functional nanostructures that can be employed in a
variety of biomedical applications, including drug delivery for
cancer therapy (Xiong et al., 2018). In this regard, MNPs
modified with nitrosonium tetrafluoroborate (NOBF4) and
polyethylene glycol (PEG) have been successfully employed for
the delivery of miR-34a in cancer cells. The miRNA-34a
conjugated nanostructures led to the downregulation of CD44
(Lee et al., 2016), a protein upregulated by autophagy and
involved in chemoresistance in oral squamous cell carcinoma
(Naik et al., 2018). The inhibition of CD44 expression showed
therapeutic effects, such as the reduction of cell migration and
invasion, suggesting that magnetic nanostructures have the
potential for miRNA-based cancer therapy.
Lipid-Based Nanoparticles
Among the many lipid-based nanocarriers that have been
developed during the last years, solid lipid nanoparticles
(SLNs) have attracted considerable interest for drug delivery
and targeting (Mishra et al., 2018). SLNs can include a cationic
component that facilitates association with anionic miRNAs and
are able to protect them from degradation during systemic
circulation (Müller et al., 2000). Interestingly, Shy et al.
developed a lipid nanoparticle system containing SLNs and
cationic dimethyl dioctadecyl ammonium bromide (DDAB) to
carry miRNA-34a in cancerous lung for CSC therapy (Shi et al.,
2013). These miRNA-34a-SLNP nanocomplexes induced
B16F10-CD44+ cell apoptosis and inhibited cell migration by
negatively regulating the cell surface protein CD44.July 2020 | Volume 11 | Article 1141
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Sharma et al. Nanomaterials and miRNA-34a DeliveryMoreover, the nanoformulationswere also effective in inhibiting
B16F10-CD44+tumordevelopmentandtumorigenicity invivo (Shi
et al., 2013).
However, when miRNA-34a and paclitaxel (PTX), an
inhibitor of microtubules dynamic (Jordan and Wilson, 2004),
were coincorporated into SLNs, the combination of these two
drugs could cooperatively and more efficiently induce cell
apoptosis and inhibit B16F10-CD44+ development in in vitro
and in vivo models through different mechanisms (Shi
et al., 2014).
Apart from SLNs, it has been shown that liposome-
polycation-hyaluronic acid (LPH) nanoparticles could
systemically deliver therapeutic siRNA into the tumor site with
relatively low toxicity (Li et al., 2008). In this regard, Huang et al.
employed LPH nanoparticles modified with PEG and tumor-
targeting single-chain antibody fragment (scFv) for systemic
delivery of the anti-autophagic miRNA-34a in experimental
lung metastasis of murine B16F10 melanoma (Chen et al.,
2010). Interestingly, miRNA-34a was found to inactivate the
MAPK pathway, leading to therapeutic activity in B16F10
melanoma cells (Chen et al., 2010). MAPK pathway has been
shown to induce autophagy through phosphorylation of c-Jun/c-
Fos transcription factors, which in turn lead transcription of
autophagy-related genes (Zhou et al., 2015; Lee et al., 2019).
Polymeric Nanoparticles
Amine terminated polyamidoamines (PAMAMs) are a class of
synthetic polymers that have been used as nanocarriers because
of their unique properties, such as highly branched structure,
water-solubility, high charge density, and numerous amine
groups for further modification (Han et al., 2018). Besides,
conjugation with specific tumor-targeted ligands is an effective
way for facilitating the intracellular delivery of PAMAMs in a
receptor-mediated endocytosis manner (Chen et al., 2017).
Phenylboronic acid (PBA) exhibits a high affinity with sialic
acid (SA), which is overexpressed in various types of tumor cells
(Narayanan, 1994), making it a promising tumor-targeted ligand
(Jia et al., 2014).
In a recent work, PBA was successfully attached to a PAMAM
surface to obtain a functional PAMAM (PPP), which has been
employed for miRNA-34a delivery in gastric carcinoma cell line
BGC-823 (Song et al., 2019). Interestingly, PPP/miRNA-34a
nanocomplexes were found to counteract the autophagic
Notch-1 signaling pathway resulting in the induction of
apoptosis and the inhibition of cell migration and invasion
(Song et al., 2019).
Alternatively, PAMAM may be conjugated with aptamers to
generate nanocomplexes, which display several properties, such
as high affinity and specificity to the target molecules, less
toxicity, and rapid tissue penetration (Tan et al., 2011). In this
regard, miRNA-34a has been encapsulated into S6 aptamer
conjugated dendrimer to form lung cancer-targeted delivery
nanoparticles (PAM-Ap/pMiRNA-34a NPs) (Wang et al.,
2015a). The aptamer conjugation improved cellular uptake of
miRNA-34, which targeted important genes involved in
autophagy regulation, such as Bcl-2 and p53 (Lindqvist et al.,Frontiers in Pharmacology | www.frontiersin.org 102014; Mrakovcic and Fröhlich, 2018). Thus, PAM-Ap/pMiRNA-
34a-NPs showed therapeutic activity by inhibiting cell growth,
migration, invasion and by inducing apoptosis of lung cancer
cells (Wang et al., 2015a).
These studies provide novel therapeutic strategies, based on
dendrimer nanoparticles, to deliver tumor suppressor miRNA-
34 in cancer cells to target autophagy-related mechanisms and
counteract tumor progression and cancer growth.
Natural polyamines, such as spermidine and spermine, are
key regulators of cell growth, differentiation, and survival (Pegg
and Casero, 2011). Recently, spermidine was found to induce
autophagy by inhibiting the lysine acetyl transferase E1A-
binding protein p300 (EP300) (Pietrocola et al., 2015). In
cancer, dysregulation of polyamine metabolism promotes
tumor development and progression (Lu et al., 2011) and
represents a promising target in cancer chemotherapy (Basuroy
and Gerner, 2006).
In this sense, in a study performed by Oupický et al.,
biodegradables nanoparticles synthesized from a polyamine
analog N1, N11-bisethylnorspermine (BENSpm) were
employed to efficiently deliver miR-34a in colorectal cancer
cells (Xie et al., 2017). After treatment with an intracellular
stimulus, these nanostructures could disassemble in the cytosol
releasing both the miRNA-34a and BENSpm, which exerted a
therapeutic function by downregulating Bcl-2 and inducing the
expression of enzymes involved in polyamine catabolism, such as
SMOX and SSAT (Stewart et al., 2018).
The ability of these biodegradable nanocarriers to deliver
therapeutic miRNA-34a and inhibit polyamine metabolism may
provide an efficient approach to combination nanomedicines for
autophagy inhibition in cancer therapy.
Recent studies have evidenced that self-assembly strategies
are useful tools to generate various nanomaterials for drug
delivery (Declerck et al., 1990; Naito et al., 2012). In this
regard, interpolyelectrolyte complexes (IPECs) can be formed
by self-assembly mixing two oppositely charged polyelectrolytes
in aqueous solution (Pergushov et al., 2012). By using the IPEC-
based approach, nucleic acids have been efficiently absorbed on
the cationic surface of the nanocomplexes and successfully
delivered in cells (Cheng et al., 2009; Kim et al., 2009).
In a work by Wang et al, miRNA-34a has been delivered into
breast cancer cells using nanocapsules prepared through IPECs-
based approach and composed of cationic protamine sulfate (PS)
and anionic Hyaluronic Acid (HA) (Wang et al., 2015b).
Notably, nanocomplex-assisted delivery of miRNA-34a
induced apoptosis and suppressed migration and proliferation
of breast cancer cells as well as reduced tumor growth in a
xenograft mouse model via targeting signaling pathways
autophagy-related, as CD44 and Notch-1 (Wang et al., 2015b).
Therefore, this biodegradable nanoplatform provides a great
potential for miRNA-34a based therapy against triple-negative
breast cancer.
Amiji et al. developed a novel drug delivery system
incorporating self-assembling hyaluronic acid-poly(ethylene
imine) (HA-PEI) and HA-poly(ethylene glycol) (HA-PEG)
nanoparticles to efficiently deliver tumor suppressor miR-34aJuly 2020 | Volume 11 | Article 1141
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(Ganesh et al., 2013; Trivedi et al., 2017). The authors reported
that miRNA-34a HA-NPs treatment resulted in decreased
glycolytic flux and antioxidant response element Nrf-2
resulting in depleted glutathione levels and ultimately,
increased in several pro-apoptotic factors in both cisplatin-
sensitive and cisplatin-resistant lung adenocarcinoma cells
(Trivedi et al., 2017). Remarkably, molecular changes in
epigenetic status on both mitochondrial (mt) and nuclear (nc)
DNA and transcription of mtDNA-encoded genes were also
observed after treatment with miRNA-34aHA-NPs. Interestingly,
some studies report the existence of a functional interplay between
glycolytic metabolism and autophagy in a positive loop that sustains
tumor progression (Watson et al., 2015; Fan et al., 2018; Jiao et al.,
2018). Therefore, the delivery of miRNA-34a through HA-PEI/HA-
PEG nanoparticles may represent a novel challenge to counteract
the Warburg effect and autophagy of cancer cells by promoting a
glycolytic to oxidative metabolism switch and inducing deep
changes in their metabolic settings, correlating with alterations of
cell proliferation.
Other studies reported that polymeric nanostructures
composed of biocompatible cationic b-cyclodextrin-PEI600
(CDP) or poly(L-lysine-graft-imidazole) (PLI) were loaded
with anionic miRNA-34a and subsequently PEGylated to
protect them from degradation, thus allowing a safe and
efficient intracellular delivery (Jang et al., 2016; Fan et al., 2017).
These pH-sensitive nanoparticles released therapeutic
miRNAs in the acid tumor microenvironment, favoring its
cytoplasmic uptake by gastric and melanoma cancer cells.
The miRNA-34 loaded NPs repressed the expression of
oncogenic CD44 protein with decreased levels of Bcl-2, Oct-3/4
and Nanog genes, thus leading the suppression of CSCs-like
characteristics, induction of apoptosis, reduction of cell invasion
and metastasis and tumor growth inhibition in xenograft gastric
cancer models (Jang et al., 2016; Fan et al., 2017).
These polymer-based strategies of miRNA-34a delivery might
represent novel therapeutic challenges with highly selective
tumor cell death and tumor growth inhibition in CD44-
positive tumors, thus opening a therapeutic window for
autophagy inhibition for cancer treatment.
Biopolymer-Based Nanoparticles
Nanomaterials based on bovine serum albumin (BSA) are
nontoxic, nonantigenic, and biodegradable polymers and have
been widely exploited in drug delivery (Rhaese et al., 2003). The
anionic side-chain carboxylic groups can be modified with a
cationic amino group to obtain cationic bovine serum albumin
(CBSA) (Fischer et al., 2001). This cationic structure can be
conjugated to nanoparticles and act as a safe drug delivery system
for nucleic acids (Han et al., 2014).
In this regard, core–shell nanocarriers coated by CBSA were
developed for delivery of miRNA-34a and the chemotherapeutic
drug docetaxel (DTX) for a cosynergistic treatment of metastatic
breast cancer (Zhang et al., 2017). The coloaded nanocarriers
(CNCs) could internalize through the caveolae-mediated
pathway and exerted therapeutic effect by inducing cytotoxicity
in vitro and by inhibiting tumor growth and metastasis in 4T1-Frontiers in Pharmacology | www.frontiersin.org 11tumor-bearing mice models (Zhang et al., 2017). Thus, these
nanocarriers represent new nanoplatforms for the delivery of
therapeutic miRNA-34 and provide a promising strategy for the
treatment of metastatic breast cancer.
Chitosan, a partially deacetylated derivative of chitin
composed of N-acetylglucosamine, has emerged as significant
biopolymer for drug delivery because of its unique chemical
proprieties such as biocompatibility, biodegradability, low
toxicity, and easy modification (Mohammed et al., 2017). In
a study performed by Cosco et al., safe chitosan/PLGA
nanocomplexes have been developed that were able to
efficiently encapsulate and deliver miRNA-34a in order to
provide a new tool for the treatment of multiple myeloma
(Cosco et al., 2015). These nanostructures led to a significant in
vitro antitumor effect by reducing the proliferative capabilities
of multiple myeloma cells. Moreover, the systemic injection of
miRNA-34a-loaded nanoparticles significantly inhibited tumor
growth through the downregulation of Bcl-2 and CDK6
expression and improved the survival of multiple myeloma
xenografts in NOD-SCID mice (Cosco et al., 2015).
Among the various polymeric nanocomplex systems, hyaluronic
acid-chitosan nanoparticles (HA-CS NPs) have been extensively
studied. In addition to its biocompatibility and biodegradability, HA
backbone possesses tumor-targeting properties through specific
binding to CD44, an integral membrane glycoprotein
overexpressed on the surface of various tumor cells (Aruffo et al.,
1990) that makes it as an ideal polymer carrier for systemic drug
delivery applications (De La Fuente et al., 2008).
It has been reported that HA-CS nano-complexes were able to
simultaneously encapsulate and deliver positively charged
Doxorubicin (DOX) and negatively charged miRNA-34a
mimics into triple-negative breast cancer cells for improved
chemotherapeutic effects (Deng et al., 2014). Interestingly,
through the restoration of endogenous miRNA-34a levels,
these nanoformulations synergistically enhanced antitumor
effects of DOX in both in vitro and in vivo models by
suppressing the expression of nonpump resistance and anti-
apoptotic Bcl-2 protein. In addition, the delivery of miRNA-34a
inhibited breast cancer cell migration via targeting Notch-1
signaling (Deng et al., 2014). Hence, nanosystem-based
codelivery of chemotherapeutic agents and tumor suppressor
miRNA-34a may be a promising combined therapeutic strategy
for enhanced antitumor therapy.CONCLUSIONS
The discovery and characterization of noncoding RNAs in the
last 20 years have opened a new layer in the understanding of
gene expression physiology as well as novel therapeutic
strategies. In particular, various miRNAs, and miRNA-34a in
particular, have been characterized as powerful tools regulating
the expression of key genes relevant in the development of a
disease, such as the control of autophagy during carcinogenesis.
However, despite many years of intense study, the
translational impact on this knowledge is not satisfactory.
Specific biologic characteristic of miRNAs, such as poorJuly 2020 | Volume 11 | Article 1141
Sharma et al. Nanomaterials and miRNA-34a Deliverychemical stability and lowmembrane permeability, may preclude
their use in clinics. For this purpose, nanotechnology has
developed a bunch of new approaches aimed at enhancing the
in vivo stability and at facilitating the delivery of specific miRNAs
to the site of disease.
Thus, the use of several nanomaterials to deliver therapeutic
nucleic acids, such as miRNA-34a, in cancer cells may result in
the inhibition of protective autophagy leading to a tumor
suppressor phenotype such as apoptosis induction, increased
chemosensitivity and therapeutic efficacy.
The high potentiality of the use of encapsulated miRNAs is
supported by the generation of MRX34, a lipid nanoparticle filled
with miR-34 mimics, that has been the first microRNA-associated
therapeutic drug tested in a clinical trial (Zhang et al., 2019). Indeed,
a study on adults affected by solid tumors refractory to standard
treatment that have been treated twice weekly for three weeks in 4-
week cycles with MRX34 showed that this formulation exerts an
evident antitumoral activity (Beg et al., 2017). Interestingly, the
administered MRX34 was also found to be present in various
tissues, including liver, bone marrow, spleen, mammary gland, and
lung (Kelnar and Bader, 2015), thus supporting its application in
the treatment of numerous cancer types.
Another evidence of the therapeutic application of delivered
miRNA has been proposed by the use of the coencapsulated miR-
34a and let-7b to NSCLC mice resistant to conventional anticancer
therapy. The obtained data showed that the dual treated animals
have a reduced tumor burden and a prolonged survival (Kasinski
et al., 2015). Taking into account these data and the here reported
formulations and applications of miRNA-34a delivery, the
therapeutic usefulness of the development of novel miR-34a
formulations may help to successfully achieve the clinical trial.Frontiers in Pharmacology | www.frontiersin.org 12However, despite the potential advantages of the described
nanoparticles, it is necessary to remember that the use of these
nanomedicines may display some toxicity. Indeed, in some cases,
nanomaterials may overstimulate autophagy in healthy tissues
leading to dangerous effects, including inflammation, oxidative
stress, and neoplastic transformation (Cordani and Somoza,
2019). Hence, it should be kept in mind that such
nanostructures can produce undesired side effects whereby
even if miRNA-34a is delivered in cancer cells, autophagy
might increase in the same way by eliminating the beneficial
effect of that therapeutic molecule.
In conclusion, deeper integration of knowledge on the role of
autophagy in tumors with the recent advances in nanomedicine
may allow an effective use of microRNA in the therapy of tumors.AUTHOR CONTRIBUTIONS
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